Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John C Bell

Showing results (31-40 of 199) with videos related to

Pageof 20
Sort By:
Current Opinion in Molecular Therapeutics|January 30, 2008
Innate immunity, tumor microenvironment and oncolytic virus therapy: friends or foes?Marianne M Stanford, Caroline J Breitbach, John C Bell, et al.
Expert Opinion on Biological Therapy|April 17, 2020
Engineering vaccinia virus as an immunotherapeutic battleship to overcome tumor heterogeneityAdrian Pelin, Stephen Boulton, Levi A Tamming, et al.
Nature Reviews. Cancer|November 19, 2005
Recent progress in the battle between oncolytic viruses and tumoursKelley A Parato, Donna Senger, Peter A J Forsyth, et al.
Trends in Immunology|August 24, 2017
cGAS-STING and Cancer: Dichotomous Roles in Tumor Immunity and DevelopmentKevin W Ng, Erin A Marshall, John C Bell, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 27, 2008
Translation of targeted oncolytic virotherapeutics from the lab into the clinic, and back again: a high-value iterative loopTa-Chiang Liu, Tae-Ho Hwang, John C Bell, et al.
Expert Opinion on Biological Therapy|August 13, 2008
Development of targeted oncolytic virotherapeutics through translational researchTa-Chiang Liu, Tae-Ho Hwang, John C Bell, et al.
Nature Reviews. Cancer|July 4, 2014
Going viral with cancer immunotherapyBrian D Lichty, Caroline J Breitbach, David F Stojdl, et al.
Current Pharmaceutical Biotechnology|July 12, 2011
Targeted and armed oncolytic poxviruses for cancer: the lead example of JX-594Caroline J Breitbach, Steve H Thorne, John C Bell, et al.
Trends in Molecular Medicine|May 4, 2004
Vesicular stomatitis virus: re-inventing the bulletBrian D Lichty, Anthony T Power, David F Stojdl, et al.
Plos Pathogens|January 24, 2014
From scourge to cure: tumour-selective viral pathogenesis as a new strategy against cancerCarolina S Ilkow, Stephanie L Swift, John C Bell, et al.
Pageof 20

Showing results (31-40 of 199) with videos related to

Sort By:
Pageof 20
Current Opinion in Molecular Therapeutics|January 30, 2008
Innate immunity, tumor microenvironment and oncolytic virus therapy: friends or foes?Marianne M Stanford, Caroline J Breitbach, John C Bell, et al.
Expert Opinion on Biological Therapy|April 17, 2020
Engineering vaccinia virus as an immunotherapeutic battleship to overcome tumor heterogeneityAdrian Pelin, Stephen Boulton, Levi A Tamming, et al.
Nature Reviews. Cancer|November 19, 2005
Recent progress in the battle between oncolytic viruses and tumoursKelley A Parato, Donna Senger, Peter A J Forsyth, et al.
Trends in Immunology|August 24, 2017
cGAS-STING and Cancer: Dichotomous Roles in Tumor Immunity and DevelopmentKevin W Ng, Erin A Marshall, John C Bell, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 27, 2008
Translation of targeted oncolytic virotherapeutics from the lab into the clinic, and back again: a high-value iterative loopTa-Chiang Liu, Tae-Ho Hwang, John C Bell, et al.
Expert Opinion on Biological Therapy|August 13, 2008
Development of targeted oncolytic virotherapeutics through translational researchTa-Chiang Liu, Tae-Ho Hwang, John C Bell, et al.
Nature Reviews. Cancer|July 4, 2014
Going viral with cancer immunotherapyBrian D Lichty, Caroline J Breitbach, David F Stojdl, et al.
Current Pharmaceutical Biotechnology|July 12, 2011
Targeted and armed oncolytic poxviruses for cancer: the lead example of JX-594Caroline J Breitbach, Steve H Thorne, John C Bell, et al.
Trends in Molecular Medicine|May 4, 2004
Vesicular stomatitis virus: re-inventing the bulletBrian D Lichty, Anthony T Power, David F Stojdl, et al.
Plos Pathogens|January 24, 2014
From scourge to cure: tumour-selective viral pathogenesis as a new strategy against cancerCarolina S Ilkow, Stephanie L Swift, John C Bell, et al.
Pageof 20